PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383312
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1383312
Endocrinology Drugs Market Forecasts to 2030 - Global Analysis By Therapy Area, Distribution Channel, Route of Administration, End User and By Geography.
According to Stratistics MRC, the Global Endocrinology Drugs Market is accounted for $6.25 billion in 2023 and is expected to reach $15.93 billion by 2030 growing at a CAGR of 14.3% during the forecast period. Endocrinology drugs are pharmaceutical substances designed to target and regulate the functions of the endocrine system. These drugs are used to treat a wide range of endocrine disorders and conditions, such as diabetes, thyroid disorders, adrenal gland disorders, and hormonal imbalances. These drugs can be administered in various forms, including oral medications, injections, and topical treatments, depending on the specific condition and the hormone involved.
According to the International Diabetic Foundation (IDF) 2021 update, approximately 537 million adults (20-79 years) were living with diabetes in 2021.
Market Dynamics:
Driver:
Growing prevalence of endocrine disorders
The growing prevalence of endocrine disorders is a significant driver of the endocrinology drug market. Lifestyle changes, including sedentary behaviour and poor dietary habits, have led to an increase in conditions like diabetes and obesity, both of which often require endocrinology medications for management. The increasing prevalence of hormonal imbalances and associated diseases has raised concerns and been attributed to environmental factors, such as exposure to endocrine-disrupting substances. Furthermore, these combined factors create a sustained demand for endocrinology drugs, providing growth for pharmaceutical companies to develop and market innovative treatments that address the needs of an expanding patient population.
Restraint:
Research and development costs
Research and Development (R&D) costs are a significant restraint in the endocrinology drugs market. Developing new endocrinology medications demands substantial financial investments, often spanning many years and clinical trials. High R&D expenditures can lead to financial strain for pharmaceutical companies, especially if promising drugs fail in late-stage trials. These costs contribute to elevated drug prices, attracting scrutiny from healthcare payers and governments. The need for rigorous safety and efficacy testing further increases the financial burden. Balancing the imperative for innovation with the substantial R&D expenses is a challenging restraint, making it essential for pharmaceutical firms to carefully select and prioritize potential drug candidates in the highly competitive endocrinology market.
Opportunity:
Development of combination therapies
Combination therapies have emerged as a promising opportunity in the field of endocrinology, offering potential benefits for the treatment of various endocrine disorders. By combining different drugs or treatment approaches, combination therapies can provide synergistic effects, improving treatment outcomes and patient response rates. They can also help address issues such as drug resistance and reduce the risk of adverse effects associated with high doses of a single medication. Moreover, combination therapies offer the potential to target specific disease mechanisms or pathways simultaneously, leading to more comprehensive and personalised treatment strategies. This approach is especially relevant in the management of conditions like diabetes, thyroid disorders, and hormonal imbalances. With ongoing advancements in understanding endocrine disorders and the development of novel therapeutic agents, the exploration and development of combination therapies present a significant opportunity to optimise treatment outcomes in endocrinology. Thus, there is lucrative growth for market expansion.
Threat:
Regulatory challenges
Regulatory challenges present a substantial threat to the endocrinology market. The development, approval, and commercialization of endocrinology drugs are subject to stringent and evolving regulations. Regulatory agencies, such as the FDA, impose rigorous standards to ensure safety and efficacy, which can lead to protracted approval timelines and high compliance costs. Compliance with these standards demands substantial financial and human resources, potentially discouraging investment in research and development. Additionally, changes in regulatory requirements can impact the market landscape, necessitating constant adaptation. Thus, these challenges are hampering market growth.
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the endocrinology drugs market. The healthcare system's focus on managing the virus led to disruptions in the diagnosis and treatment of endocrine disorders. Additionally, supply chain disruptions and drug shortages posed challenges in maintaining a steady supply of endocrinology drugs. However, the pandemic also accelerated telehealth adoption, offering new avenues for remote monitoring and prescription management. Ultimately, the endocrinology drugs market faced a complex landscape of delays, drug shortages, and evolving healthcare delivery models during the pandemic.
The Diabetes Drugs segment is expected to be the largest during the forecast period
The Diabetes Drugs segment is estimated to hold the largest share, owing to the increase in cases of diabetes, the rise in the development of diabetic drugs, and the increase in investment in the development of diabetic drug research. Also, the high prevalence of diabetes across the globe and the unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment. Furthermore, a rise in investments in the development of diabetic drugs by key players or government agencies is expected to fuel the growth of the segment. Hence, due to the rise in cases of diabetes and the increase in research funding for the development of diabetic drugs, the diabetes segment is expected to witness significant growth.
The Hospital Pharmacies segment is expected to have the highest CAGR during the forecast period
The Hospital Pharmacies segment is anticipated to have lucrative growth during the forecast period. Endocrinology drugs are designed to address hormonal imbalances and related conditions. In this segment, hospital pharmacies serve as key distribution points; ensuring patients receive the right medications in a controlled and timely manner. They also play a pivotal role in patient education, helping individuals understand the proper use and potential side effects of endocrinology drugs. Moreover, hospital pharmacies collaborate with endocrinologists to ensure tailored treatment plans, often involving complex medication regimens, are effectively implemented. Hence, hospital pharmacies are vital components of the endocrinology drugs market, facilitating optimal patient care and management of endocrine disorders.
Region with largest share:
North America commanded the largest market share during the extrapolated period due to the growing ageing population, which increases the risk of endocrine disorders. Increases in the incidence of a number of endocrine disorders, including diabetes, insulin resistance, and thyroid issues, can be attributed to the rise in obesity cases in the US and Canada. The most prevalent endocrine condition, diabetes, has a high prevalence and contributes significantly to regional market income. Moreover, the American Association of Diabetes Educators and the American Diabetes Association, among other groups, are driving the expansion of the patient education sector in the region.
Region with highest CAGR:
Asia- Pacific region is expected to witness profitable growth over the projection period, owing to a rise in the prevalence of growth hormone deficiency and the expected growth of research and development in the region. The market for endocrinology drugs in the area will benefit from an increase in the incidence of cancers related to the endocrine system and diabetes, including end-stage renal disease. Furthermore, throughout the duration of the estimated time frame, rising public awareness of infrequently occurring endocrine disorders-such as dyspareunia and vulvar and vaginal atrophy caused by menopause-is anticipated to fuel the market's growth. Various research paradigms carried out, such as the introduction of novel drugs and combination pharmaceuticals for the treatment of endocrine disorders, are also expected to boost the region's growth.
Key players in the market
Some of the key players in the Endocrinology Drugs Market include: Abbott Laboratories, Eli Lilly And Company, F. Hoffmann La Roche Ltd., Novartis International AG, Pfizer Inc., Alacer Corporation , Novo Nordisk A/S, Facet Biotech Corporation, Sanofi, Takeda Pharmaceutical Company Limited, Merck KGaA, AstraZeneca Plc, Lee Pharmaceuticals, MannKind, Acerus Pharmaceuticals Corp, Bayer AG, Endo International Plc, Beta Cell NV, Hanmi Pharm Co. Ltd and Ipsen Pharma.
Key Developments:
In March 2023, Eton Pharmaceuticals, a pharmaceutical company focused on developing and commercializing treatments for rare diseases, acquired a rare disease product candidate, ET-600, from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for treating an endocrinology condition estimated to impact less than 5,000 pediatric patients in the United States.
In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, received approval from the Drug Controller-General of India (DCGI) for their product Lobeglitazone, an anti-diabetic drug. The drug is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.
Therapy Areas Covered:
- Diabetes Drugs
- Growth Hormone Disorders
- Thyroid Hormone Disorder Drugs
- Testosterone Replacement Therapy
- Osteoporosis
- Adrenal insufficiency
- Hypogonadism
- Other Therapy Areas
Distribution Channels Covered:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Other Distribution Channels
Route of Administrations Covered:
- Oral
- Transdermal
- Injectable
End Users Covered:
- Ambulatory Surgical Centers
- Hospitals
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Endocrinology Drugs Market, By Therapy Area
- 5.1 Introduction
- 5.2 Diabetes Drugs
- 5.3 Growth Hormone Disorders
- 5.4 Thyroid Hormone Disorder Drugs
- 5.5 Testosterone Replacement Therapy
- 5.6 Osteoporosis
- 5.7 Adrenal insufficiency
- 5.8 Hypogonadism
- 5.9 Other Therapy Areas
6 Global Endocrinology Drugs Market, By Distribution Channel
- 6.1 Introduction
- 6.2 Hospital Pharmacies
- 6.3 Online Pharmacies
- 6.4 Retail Pharmacies
- 6.5 Other Distribution Channels
7 Global Endocrinology Drugs Market, By Route of Administration
- 7.1 Introduction
- 7.2 Oral
- 7.3 Transdermal
- 7.4 Injectable
8 Global Endocrinology Drugs Market, By End User
- 8.1 Introduction
- 8.2 Ambulatory Surgical Centers
- 8.3 Hospitals
- 8.4 Other End Users
9 Global Endocrinology Drugs Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Abbott Laboratories,
- 11.2 Eli Lilly And Company
- 11.3 F. Hoffmann La Roche Ltd.
- 11.4 Novartis International AG
- 11.5 Pfizer Inc.
- 11.6 Alacer Corporation
- 11.7 Novo Nordisk A/S
- 11.8 Facet Biotech Corporation
- 11.9 Sanofi
- 11.10 Takeda Pharmaceutical Company Limited
- 11.11 Merck KGaA
- 11.12 AstraZeneca Plc
- 11.13 Lee Pharmaceuticals
- 11.14 MannKind
- 11.15 Acerus Pharmaceuticals Corp
- 11.16 Bayer AG
- 11.17 Endo International Plc
- 11.18 Beta Cell NV
- 11.19 Hanmi Pharm Co. Ltd
- 11.20 Ipsen Pharma
List of Tables
- Table 1 Global Endocrinology Drugs Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Endocrinology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 3 Global Endocrinology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 4 Global Endocrinology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 5 Global Endocrinology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 6 Global Endocrinology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 7 Global Endocrinology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 8 Global Endocrinology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 9 Global Endocrinology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 10 Global Endocrinology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 11 Global Endocrinology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 12 Global Endocrinology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 13 Global Endocrinology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 14 Global Endocrinology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 15 Global Endocrinology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 16 Global Endocrinology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 17 Global Endocrinology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 18 Global Endocrinology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 19 Global Endocrinology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 20 Global Endocrinology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 21 Global Endocrinology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 22 Global Endocrinology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 23 Global Endocrinology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 24 North America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
- Table 25 North America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 26 North America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 27 North America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 28 North America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 29 North America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 30 North America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 31 North America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 32 North America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 33 North America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 34 North America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 35 North America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 36 North America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 37 North America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 38 North America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 39 North America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 40 North America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 41 North America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 42 North America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 43 North America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 44 North America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 45 North America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 46 North America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 47 Europe Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
- Table 48 Europe Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 49 Europe Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 50 Europe Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 51 Europe Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 52 Europe Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 53 Europe Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 54 Europe Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 55 Europe Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 56 Europe Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 57 Europe Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 58 Europe Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 59 Europe Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 60 Europe Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 61 Europe Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 62 Europe Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 63 Europe Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 64 Europe Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 65 Europe Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 66 Europe Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 67 Europe Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 68 Europe Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 69 Europe Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 70 Asia Pacific Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
- Table 71 Asia Pacific Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 72 Asia Pacific Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 73 Asia Pacific Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 74 Asia Pacific Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 75 Asia Pacific Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 76 Asia Pacific Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 77 Asia Pacific Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 78 Asia Pacific Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 79 Asia Pacific Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 80 Asia Pacific Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 81 Asia Pacific Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 82 Asia Pacific Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 83 Asia Pacific Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 84 Asia Pacific Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 85 Asia Pacific Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 86 Asia Pacific Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 87 Asia Pacific Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 88 Asia Pacific Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 89 Asia Pacific Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 90 Asia Pacific Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 91 Asia Pacific Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 92 Asia Pacific Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 93 South America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
- Table 94 South America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 95 South America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 96 South America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 97 South America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 98 South America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 99 South America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 100 South America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 101 South America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 102 South America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 103 South America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 104 South America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 105 South America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 106 South America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 107 South America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 108 South America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 109 South America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 110 South America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 111 South America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 112 South America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 113 South America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 114 South America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 115 South America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 116 Middle East & Africa Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
- Table 117 Middle East & Africa Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
- Table 118 Middle East & Africa Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
- Table 119 Middle East & Africa Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
- Table 120 Middle East & Africa Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
- Table 121 Middle East & Africa Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
- Table 122 Middle East & Africa Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
- Table 123 Middle East & Africa Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
- Table 124 Middle East & Africa Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
- Table 125 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
- Table 126 Middle East & Africa Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 127 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
- Table 128 Middle East & Africa Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 129 Middle East & Africa Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
- Table 130 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 131 Middle East & Africa Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 132 Middle East & Africa Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
- Table 133 Middle East & Africa Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
- Table 134 Middle East & Africa Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
- Table 135 Middle East & Africa Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
- Table 136 Middle East & Africa Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
- Table 137 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
- Table 138 Middle East & Africa Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
